+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


VEREGEN Drug Profile, 2019

  • ID: 4726955
  • Report
  • February 2020
  • Region: Global
  • 47 pages
  • thinkBiotech LLC
1 of 4


VEREGEN Drug Profile, 2019 is part of a deep library of business intelligence on biopharmaceutical drugs.

The report focuses on VEREGEN and covers the following critical aspects of this drug:
  • United States patents
  • Expired United States patents
  • European supplementatry protection certificates (SPCs)
  • Clinical trials
  • Annual sales revenues
  • Finished product suppliers
About the Researcher

The researcher is a provider of global business intelligence on biologic and small-molecule drugs, dedicated to helping clients make better decisions. Critical information on global drug patents is incorporated with litigation intelligence, drug prices, and historic sales figures to help users discover commercial opportunities and forecast future revenue events. Since 2005 the researcher has served hundreds of large and small companies in more than 65 countries.
Note: Product cover images may vary from those shown
2 of 4


  • Profile for VEREGEN
  • US Patents
  • Expired US Patents
  • International (ex US) Patents
  • Supplementary Protection Certificates
  • Clinical Trials
  • Annual Sales Revenues
  • Finished Product Suppliers
Note: Product cover images may vary from those shown
3 of 4


4 of 4
  • Fougera Pharms Inc
  • Pharmaderm A Division Of Fougera Pharmaceuticals Inc.
Note: Product cover images may vary from those shown